세계의 AI Drug Discovery 플랫폼 시장 예측(-2032년) : 구성요소별, 치료 분야별, 약물 유형별, 전개 모델별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global AI-Powered Drug Discovery Platforms Market is accounted for $2,462.9 million in 2025 and is expected to reach $15,705.9 million by 2032 growing at a CAGR of 30.3% during the forecast period. AI-powered drug discovery platforms are advanced computational systems that leverage artificial intelligence to accelerate and optimize the process of identifying, designing, and testing new pharmaceutical compounds. These platforms analyze vast biomedical datasets-including genomics, proteomics, and clinical records-to predict drug-target interactions, assess toxicity, and simulate molecular behavior. By automating traditionally time-consuming tasks, they reduce R&D costs and shorten development timelines. Machine learning algorithms enable continuous refinement of models, improving accuracy and success rates. Widely used in precision medicine, oncology, and rare disease research, AI-powered platforms are transforming drug discovery into a faster, data-driven, and more efficient process.

Market Dynamics:

Driver:

Accelerated Drug Development Timelines

Accelerated drug development timelines are a key driver for AI-powered drug discovery platforms. These systems streamline compound screening, target identification, and toxicity prediction, significantly reducing the time required for preclinical and clinical phases. By automating data analysis and simulating molecular interactions, AI enables faster decision-making and early-stage validation. This efficiency is crucial for pharmaceutical companies aiming to bring therapies to market quickly, especially in response to emerging diseases and competitive pressures.

Restraint:

Data Quality and Integration Issues

Data quality and integration issues pose a major restraint to the AI-powered drug discovery market. Inconsistent, incomplete, or siloed biomedical data can impair model accuracy and reliability. Integrating diverse datasets-such as genomics, proteomics, and clinical records-requires advanced infrastructure and standardization. Without clean, interoperable data, AI algorithms struggle to generate meaningful insights, limiting their effectiveness. Addressing these challenges is essential to unlock the full potential of AI in pharmaceutical research and development.

Opportunity:

Rising R&D Costs in Pharma

Rising R&D costs in the pharmaceutical industry present a significant opportunity for AI-powered drug discovery platforms. Traditional drug development is expensive and time-consuming, often requiring billions in investment. AI reduces costs by automating early-stage research, improving candidate selection, and minimizing trial failures. As companies seek cost-effective solutions to maintain innovation and profitability, AI platforms offer a scalable, data-driven approach to streamline operations and enhance productivity across the drug development lifecycle.

Threat:

High Initial Investment

High initial investment is a notable threat to the adoption of AI-powered drug discovery platforms. Building robust AI infrastructure requires substantial funding for data acquisition, computing resources, and skilled personnel. Smaller firms may struggle to afford these technologies, limiting market penetration. Additionally, long development cycles and uncertain ROI can deter stakeholders. Without financial incentives or collaborative models, the upfront cost barrier may slow the transition from traditional methods to AI-driven drug discovery.

Covid-19 Impact:

The COVID-19 pandemic highlighted the urgency of rapid drug development, accelerating interest in AI-powered platforms. These systems supported vaccine and therapeutic research by analyzing vast datasets and predicting molecular interactions. However, supply chain disruptions and resource reallocation temporarily slowed adoption. Post-pandemic, the industry is prioritizing digital transformation and resilience, with AI playing a central role in future preparedness. The pandemic ultimately reinforced the value of AI in enabling faster, data-driven pharmaceutical innovation.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to account for the largest market share during the forecast period due to the complexity and urgency of cancer research. AI-powered platforms help identify novel targets, predict drug responses, and personalize treatments based on genetic profiles. With rising cancer incidence and demand for precision medicine, pharmaceutical companies are investing heavily in AI tools to accelerate oncology drug development. These platforms enhance clinical trial design and biomarker discovery, making oncology the largest and most impactful application area.

The biotechnology firms segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biotechnology firms segment is predicted to witness the highest growth rate because these agile, innovation-driven companies are rapidly adopting AI to enhance drug discovery pipelines and reduce development costs. With access to cutting-edge technologies and specialized datasets, biotech firms leverage AI for target identification, molecule design, and predictive modeling. Their flexibility and focus on niche therapies position them as key drivers of growth in the AI-powered drug discovery market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to its expanding pharmaceutical industry, growing investments in AI, and supportive government initiatives. Countries like China, India, and Japan are advancing digital healthcare infrastructure and fostering collaborations between tech and biotech sectors. The region's large patient population and rich biomedical data resources further enhance AI model training and deployment. These factors collectively position Asia Pacific as a dominant force in the global market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR due to strong R&D capabilities, advanced AI infrastructure, and strategic partnerships between tech giants and pharmaceutical companies. The U.S. leads in AI innovation and regulatory support, fostering rapid adoption across healthcare and biotech sectors. Increasing demand for precision medicine, coupled with robust investment in AI startups, is fueling growth. North America's leadership in digital transformation and drug development makes it the fastest-growing region in this market.

Key players in the market

Some of the key players in AI-Powered Drug Discovery Platforms Market include Atomwise, BenevolentAI, Insilico Medicine, Recursion Pharmaceuticals, Schrodinger, Exscientia, Healx, Cyclica, LabGenius, Numerate, Owkin, Relay Therapeutics, Generate Biomedicines, Cloud Pharmaceuticals and NVIDIA Corporation.

Key Developments:

In September 2025, NVIDIA and Intel have joined forces to co-develop custom AI infrastructure and personal computing products. This strategic partnership aims to seamlessly integrate NVIDIA's accelerated computing capabilities with Intel's leading CPU technologies, utilizing NVIDIA's NVLink to deliver cutting-edge solutions across hyperscale, enterprise, and consumer markets.

In September 2025, OpenAI and NVIDIA have embarked on a strategic partnership to deploy at least 10 gigawatts of NVIDIA systems, marking a significant leap in AI infrastructure development. This collaboration aims to establish a robust foundation for training and operating next-generation AI models, propelling both companies toward the realization of superintelligence.

Components Covered:

• Software
• Services

Therapeutic Areas Covered:

• Oncology
• Neurology
• Cardiovascular Diseases
• Infectious Diseases
• Immunology & Inflammation
• Metabolic Disorders
• Rare & Orphan Diseases
• Other Therapeutic Areas

Drug Types Covered:

• Small Molecules
• Biologics
• Cell & Gene Therapy Candidates

Deployment Models Covered:

• Cloud-Based Platforms
• On-Premises Solutions
• Hybrid Models

End Users Covered:

• Pharmaceutical Companies
• Biotechnology Firms
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Healthcare Providers

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global AI-Powered Drug Discovery Platforms Market, By Component

• 5.1 Introduction
• 5.2 Software
• 5.3 Services

6 Global AI-Powered Drug Discovery Platforms Market, By Therapeutic Area

• 6.1 Introduction
• 6.2 Oncology
• 6.3 Neurology
• 6.4 Cardiovascular Diseases
• 6.5 Infectious Diseases
• 6.6 Immunology & Inflammation
• 6.7 Metabolic Disorders
• 6.8 Rare & Orphan Diseases
• 6.9 Other Therapeutic Areas

7 Global AI-Powered Drug Discovery Platforms Market, By Drug Type

• 7.1 Introduction
• 7.2 Small Molecules
• 7.3 Biologics
  • 7.3.1 Monoclonal Antibodies
  • 7.3.2 Peptides & Proteins
  • 7.3.3 RNA-based Therapeutics
• 7.4 Cell & Gene Therapy Candidates

8 Global AI-Powered Drug Discovery Platforms Market, By Deployment Model

• 8.1 Introduction
• 8.2 Cloud-Based Platforms
• 8.3 On-Premises Solutions
• 8.4 Hybrid Models

9 Global AI-Powered Drug Discovery Platforms Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical Companies
• 9.3 Biotechnology Firms
• 9.4 Contract Research Organizations (CROs)
• 9.5 Academic & Research Institutes
• 9.6 Healthcare Providers

10 Global AI-Powered Drug Discovery Platforms Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Atomwise
• 12.2 BenevolentAI
• 12.3 Insilico Medicine
• 12.4 Recursion Pharmaceuticals
• 12.5 Schrodinger
• 12.6 Exscientia
• 12.7 Healx
• 12.8 Cyclica
• 12.9 LabGenius
• 12.10 Numerate
• 12.11 Owkin
• 12.12 Relay Therapeutics
• 12.13 Generate Biomedicines
• 12.14 Cloud Pharmaceuticals
• 12.15 NVIDIA Corporation